The Receptor Activity-Modifying Protein 3 (RAMP3) is a member of the RAMP family, which comprises three transmembrane proteins (RAMP1-3) that modulate the trafficking and ligand specificity of G protein-coupled receptors (GPCRs), particularly the calcitonin receptor-like receptor (CALCRL). RAMP3 forms heterodimers with CALCRL to create functional receptors for peptides like adrenomedullin (AM) and calcitonin gene-related peptide (CGRP), influencing cardiovascular, metabolic, and inflammatory processes. RAMP3 is broadly expressed in tissues, including the vasculature, kidneys, and brain, and has been implicated in pathophysiological conditions such as hypertension, heart failure, cancer progression, and metabolic disorders.
RAMP3 antibodies are essential tools for detecting and studying RAMP3 expression, localization, and interaction with partner receptors. These antibodies enable research into RAMP3's role in receptor signaling dynamics, disease mechanisms, and therapeutic targeting. For example, studies suggest RAMP3 may promote tumor angiogenesis or regulate blood pressure via AM receptor activation. Validated RAMP3 antibodies are critical for techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation, ensuring specificity for distinguishing RAMP3 from other RAMPs. Recent research also explores RAMP3's dual roles in protective and pathogenic contexts, highlighting its potential as a biomarker or drug target. The development of high-affinity RAMP3 antibodies continues to advance understanding of its complex biology in health and disease.